In a target trial emulation drawing on 75,455 adults with type 2 diabetes across 12 U.S. health systems, GLP-1 receptor agonists and SGLT-2 inhibitors slashed the five-year risk of serious kidney deterioration by 40% compared with DPP-4 inhibitors — but exclusively in patients who already had albuminuria (albumin-to-creatinine ratio ≥30 mg/g). Among the 81% without albuminuria, the five-year renal event rate was virtually identical between drug classes (2.4% vs. 2.1%, risk ratio 1.10), with confidence intervals spanning no meaningful benefit.
This finding carries significant clinical weight. Guidelines increasingly position SGLT-2 inhibitors and GLP-1 agonists as preferred second-line agents for virtually all type 2 diabetes patients partly on the strength of landmark trials like CREDENCE and DAPA-CKD — but those trials overwhelmingly enrolled patients with established albuminuria or reduced GFR. This large real-world study, using rigorous target trial emulation methodology to approximate causal inference from observational data, now suggests kidney protection may not generalize to the much larger normoalbuminuric population. The practical implication is important: clinicians should prioritize these costlier agents for patients with detectable albuminuria, while the case for kidney-specific benefit in normoalbuminuric patients remains weak. Key limitations include the combined GLP-1/SGLT-2 grouping (masking potentially different effect sizes between classes), moderate follow-up of 32 months median, and residual confounding inherent to any observational design. Nonetheless, this is one of the largest and most methodologically rigorous real-world analyses to date on this question.